322 results
Page 2 of 17
6-K
EX-99.3
z0sqacp
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
eysm02r9
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm
6-K
EX-99.2
mvgolr
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
mcrfz5h79fvn
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
3mzabvd
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm
6-K
EX-99.1
szd d373x5ctu
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.2
fwox1qdt zj6
31 May 22
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
10:56am
6-K
EX-99.1
730n jl9u4z7
25 May 22
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
1:53pm
6-K
EX-99.1
xeqkqy2921wx mdjd91g
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.2
l66vwgjn2n98jc9 vie
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.3
i0cdr7kdb
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.1
xu2770ff
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
3amj8o68u2my6fee2 1v
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm
6-K
EX-99.2
21c7uao3aipntm
22 Mar 22
Sanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
2:29pm
6-K
EX-99.1
ia9h47smov63iw
4 Mar 22
Current report (foreign)
4:20pm
6-K
EX-99.2
h09mq
4 Mar 22
Current report (foreign)
4:20pm
6-K
EX-99.1
7aibs20h
24 Feb 22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
5:14pm
6-K
EX-99.3
6md08uvuot16pgkwxg94
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm